April 2026 in “International Journal of Clinical Oncology” This review found that adding immune checkpoint inhibitors to cancer treatment regimens likely increases the incidence of specific drug-related skin toxicities in adult Asian patients, highlighting the need for careful monitoring and management strategies.
November 2025 in “Skin Appendage Disorders” This study reviewed evidence on biologic drugs targeting immune cells for alopecia areata, finding mixed results: some achieved case-level hair regrowth, but controlled trials often showed limited efficacy.
December 2025 in “International Journal of Dermatology and Venereology” In this review, summarized findings suggest that emerging targeted immunotherapies may offer promising treatment options for alopecia areata by addressing the breakdown of hair follicle immune privilege.
July 2026 in “Expert Review of Clinical Immunology” This review highlights that alopecia areata is characterized by three immune endotypes, and while JAK inhibitors offer temporary control, upcoming multi-omics diagnostics and immune reprogramming strategies may achieve longer-lasting remission, according to this analysis.
August 2023 in “Research Square (Research Square)” In this study, researchers observed that Melan A, a melanocytic marker, was significantly expressed in hair follicles of alopecia areata patients and correlated with immune infiltrates, suggesting melanocytes might contribute to the autoimmune response in this condition.